DK2155229T3 - Sammensætning til transmukosal indgivelse af polypeptider - Google Patents

Sammensætning til transmukosal indgivelse af polypeptider

Info

Publication number: DK2155229T3
Authority: DK; Denmark
Prior art keywords: biologically active; active polypeptide; transmucosal; polypeptides; dosage form
Prior art date: 2007-05-01

Application number

DK08754187.6T

Other languages

English (en)

Inventor

Steve L Durfee

Gary B Thurman

Original Assignee

Cephalon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-01

Filing date

2008-05-01

Publication date

2011-05-09

2008-05-01 Application filed by Cephalon Inc filed Critical Cephalon Inc

2011-05-09 Application granted granted Critical

2011-05-09 Publication of DK2155229T3 publication Critical patent/DK2155229T3/da

Links

229920001184 polypeptide Polymers 0.000 title abstract 7
102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
238000010521 absorption reaction Methods 0.000 abstract 3
239000002552 dosage form Substances 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
239000003833 bile salt Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000007909 solid dosage form Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

DK08754187.6T 2007-05-01 2008-05-01 Sammensætning til transmukosal indgivelse af polypeptider DK2155229T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92700607P	2007-05-01	2007-05-01
PCT/US2008/005655 WO2008137054A2 (en)	2007-05-01	2008-05-01	Composition for transmucosal delivery of polypeptides

Publications (1)

Publication Number	Publication Date
DK2155229T3 true DK2155229T3 (da)	2011-05-09

Family

ID=39944167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08754187.6T DK2155229T3 (da)	2007-05-01	2008-05-01	Sammensætning til transmukosal indgivelse af polypeptider

Country Status (18)

Country	Link
US (2)	US20100111902A1 (da)
EP (2)	EP2155229B1 (da)
JP (1)	JP5611033B2 (da)
CN (1)	CN101674843A (da)
AT (1)	ATE495753T1 (da)
AU (1)	AU2008248228B2 (da)
CA (1)	CA2685853A1 (da)
CY (1)	CY1111422T1 (da)
DE (1)	DE602008004656D1 (da)
DK (1)	DK2155229T3 (da)
ES (1)	ES2359875T3 (da)
HR (1)	HRP20110273T1 (da)
IL (1)	IL201563A (da)
MX (1)	MX2009011784A (da)
NZ (1)	NZ580967A (da)
PL (1)	PL2155229T3 (da)
SI (1)	SI2155229T1 (da)
WO (1)	WO2008137054A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102770152B (zh) *	2009-11-25	2016-07-06	阿瑞斯根股份有限公司	肽类的粘膜递送
RU2519099C1 (ru) *	2012-11-08	2014-06-10	Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН)	Фармацевтическая композиция
CN104667254A (zh) *	2013-11-29	2015-06-03	中国科学院兰州化学物理研究所	一种鱼低聚肽泡腾片及其制备方法
CN104840958B (zh) *	2015-05-28	2018-03-30	广州帝奇医药技术有限公司	人工粘膜组合物及其制备方法和应用
IT201700120081A1 (it)	2017-10-23	2019-04-23	Biofarma S P A	Dispositivo e metodo per la somministrazione orale di principi attivi
US11911445B2 (en)	2018-01-23	2024-02-27	Gila Therapeutics, Inc.	Peptide YY pharmaceutical formulations, compositions, and methods
AU2020279976A1 (en) *	2019-05-20	2021-11-11	Poviva Corp.	Compositions comprising biologically active agents and bile salts
US12589095B2 (en)	2019-05-31	2026-03-31	Primo Pharmatech Llc	Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
US11291701B1 (en) *	2021-02-04	2022-04-05	Seed Edibles	Orally disintegrating, sublingual and buccal formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2735304A (en)		1956-02-21		toppfb haw
US142198A (en) *		1873-08-26		Improvement in windmills
US169989A (en) *		1875-11-16		Improvement in iron fences
US163838A (en) *		1875-06-01		Improvement in mariners compasses
US142197A (en) *		1873-08-26		Improvement in fanning-mills
US2613204A (en)		1952-10-07		of urea
GB697914A (en)	1949-10-24	1953-09-30	Ruf Buchhaltung Ag	Improvements in and relating to a sheet feeding and guiding device for a typewriter
BE502283A (da)	1950-03-31
US4849227A (en) *	1986-03-21	1989-07-18	Eurasiam Laboratories, Inc.	Pharmaceutical compositions
JP2911496B2 (ja)	1989-09-11	1999-06-23	帝國製薬株式会社	生理活性ポリペプチド含有高吸収性経膣剤
US5178878A (en)	1989-10-02	1993-01-12	Cima Labs, Inc.	Effervescent dosage form with microparticles
CA2094217A1 (en)	1992-04-17	1993-10-18	Yasutaka Igari	Transmucosal therapeutic composition
US5503846A (en)	1993-03-17	1996-04-02	Cima Labs, Inc.	Base coated acid particles and effervescent formulation incorporating same
US5766620A (en) *	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
WO1998043893A1 (en)	1997-04-01	1998-10-08	Cima Labs Inc.	Blister package and packaged tablet
US6024981A (en)	1997-04-16	2000-02-15	Cima Labs Inc.	Rapidly dissolving robust dosage form
US6974590B2 (en)	1998-03-27	2005-12-13	Cima Labs Inc.	Sublingual buccal effervescent
US6200604B1 (en) *	1998-03-27	2001-03-13	Cima Labs Inc.	Sublingual buccal effervescent
US20050158408A1 (en) *	1998-07-24	2005-07-21	Yoo Seo H.	Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US6210699B1 (en) *	1999-04-01	2001-04-03	Watson Pharmaceuticals, Inc.	Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
WO2005065317A2 (en)	2003-12-31	2005-07-21	Cima Labs Inc.	Effervescent oral fentanyl dosage form
KR101184138B1 (ko)	2003-12-31	2012-09-19	시마 랩스 인크.	일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
NZ548215A (en)	2003-12-31	2009-08-28	Cima Labs Inc	Effervescent oral opiate dosage form

2008
- 2008-05-01 ES ES08754187T patent/ES2359875T3/es active Active
- 2008-05-01 CA CA002685853A patent/CA2685853A1/en not_active Abandoned
- 2008-05-01 EP EP08754187A patent/EP2155229B1/en not_active Not-in-force
- 2008-05-01 DK DK08754187.6T patent/DK2155229T3/da active
- 2008-05-01 NZ NZ580967A patent/NZ580967A/en unknown
- 2008-05-01 AT AT08754187T patent/ATE495753T1/de active
- 2008-05-01 DE DE602008004656T patent/DE602008004656D1/de active Active
- 2008-05-01 MX MX2009011784A patent/MX2009011784A/es active IP Right Grant
- 2008-05-01 HR HR20110273T patent/HRP20110273T1/hr unknown
- 2008-05-01 CN CN200880014387A patent/CN101674843A/zh active Pending
- 2008-05-01 SI SI200830213T patent/SI2155229T1/sl unknown
- 2008-05-01 WO PCT/US2008/005655 patent/WO2008137054A2/en not_active Ceased
- 2008-05-01 JP JP2010506325A patent/JP5611033B2/ja not_active Expired - Fee Related
- 2008-05-01 AU AU2008248228A patent/AU2008248228B2/en not_active Ceased
- 2008-05-01 PL PL08754187T patent/PL2155229T3/pl unknown
- 2008-05-01 EP EP11151281A patent/EP2316472A1/en not_active Withdrawn
2009
- 2009-10-15 IL IL201563A patent/IL201563A/en not_active IP Right Cessation
- 2009-10-30 US US12/609,998 patent/US20100111902A1/en not_active Abandoned
2011
- 2011-04-15 CY CY20111100380T patent/CY1111422T1/el unknown
- 2011-11-22 US US13/302,868 patent/US20120076757A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2010526071A (ja)	2010-07-29
CY1111422T1 (el)	2015-08-05
US20120076757A1 (en)	2012-03-29
IL201563A (en)	2013-05-30
WO2008137054A2 (en)	2008-11-13
PL2155229T3 (pl)	2011-06-30
US20100111902A1 (en)	2010-05-06
IL201563A0 (en)	2010-05-31
ES2359875T3 (es)	2011-05-27
CN101674843A (zh)	2010-03-17
JP5611033B2 (ja)	2014-10-22
EP2155229B1 (en)	2011-01-19
MX2009011784A (es)	2009-11-13
ATE495753T1 (de)	2011-02-15
WO2008137054A3 (en)	2009-06-04
HK1141444A1 (en)	2010-11-12
AU2008248228A1 (en)	2008-11-13
EP2155229A2 (en)	2010-02-24
CA2685853A1 (en)	2008-11-13
DE602008004656D1 (de)	2011-03-03
NZ580967A (en)	2012-04-27
AU2008248228B2 (en)	2012-10-18
SI2155229T1 (sl)	2011-05-31
EP2316472A1 (en)	2011-05-04
HRP20110273T1 (hr)	2011-05-31

Publication	Publication Date	Title
CY1111422T1 (el)	2015-08-05	Συνθεση για διαβλεννογονικη παραδοση πολυπεπτιδιων
CY1123162T1 (el)	2021-10-29	Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
WO2008027854A3 (en)	2008-07-03	Pharmaceutical compositions comprising hgh for oral delivery
BRPI0418228A (pt)	2007-04-27	forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
CY1122134T1 (el)	2020-11-25	Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας
CY1119498T1 (el)	2018-03-07	Συντηγμενα πολυπεπτιδια λεπτινης-abd με ενισχυμενη διαρκεια δρασης
EA200700380A1 (ru)	2007-10-26	Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
MX2010000856A (es)	2010-04-30	Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihidropiridina y metodo para la preparacion de la misma.
IL196425A0 (en)	2009-11-18	Pharmaceutical compositions containing ibuprofen and famotidine
IL172783A0 (en)	2006-06-11	Rasgap derived peptide for selectively killing cancer cells
CY1109537T1 (el)	2014-08-13	Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
DE60329968D1 (de)	2009-12-24	Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
CO5640120A2 (es)	2006-05-31	Formulacion y metodods para el tratamiento de trombocitemia
EA201170108A1 (ru)	2011-06-30	Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
NO20055209D0 (no)	2005-11-04	Peptabody for cancerbehandling
NO20024673D0 (no)	2002-09-30	Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
ATE460934T1 (de)	2010-04-15	Pharmazeutische zubereitungen von ciprofloxacin
TW200611697A (en)	2006-04-16	Generally linear effervescent oral fentanyl dosage form and methods of administering
DK2058328T3 (da)	2011-06-27	Derivater af biologisk aktivt peptid VAPEEHPTLLTEAPLNPK
RU2004135668A (ru)	2006-05-20	Способ иммунокоррекции у коров
WO2008133952A3 (en)	2009-01-15	Transmucosal treatment with fentanyl in patients with mucositis
TW200611696A (en)	2006-04-16	Effervescent oral fentanyl dosage form and methods of administering fentanyl
EA200701010A1 (ru)	2007-10-26	Препарат гепирона с высокой дозировкой и длительным высвобождением
ATE493976T1 (de)	2011-01-15	Bakuchiol enthaltende pharmazeutische zusammensetzung zur behandlung von weiblicher osteoporose
AR048000A1 (es)	2006-03-15	Forma de dosificacion oral efervescente substancialmente lineal de fentanilo y metodos de administracion